Peptide and use thereof

An agent for suppressing blood glucose elevation, comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

An agent for improving insulin sensitivity, comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

An agent for promoting FGF21 secretion, comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

An agent for suppressing stress or protecting nerves, comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

An agent for reducing fatigue, comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for producing a hydrolysate of a whey protein comprising a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), VTQTMKGL (SEQ ID NO:
• 6), comprising hydrolyzing the whey protein with chymotrypsin.

A method for improving the intestinal barrier function, comprising administering to a subject in need thereof an effective amount of peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for suppressing blood glucose elevation, comprising administering to a subject in need thereof an effective amount of a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for improving insulin sensitivity, comprising administering to a subject in need thereof an effective amount of a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for promoting FGF21 secretion, comprising administering to a subject in need thereof an effective amount of a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for suppressing stress or protecting nerves, comprising administering to a subject in need thereof an effective amount of a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).

A method for reducing fatigue, comprising administering to a subject in need thereof an effective amount of a peptide consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO:

• 1), LIVTQTMKG (SEQ ID NO:
• 2), LIVTQTMK (SEQ ID NO:
• 3), IVTQTMKGL (SEQ ID NO:
• 4), IVTQTMKG (SEQ ID NO:
• 5), and VTQTMKGL (SEQ ID NO:
• 6).